Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. The gene discussed is MTAP; the disease is hereditary clear cell renal cell carcinoma.